BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gmyrek GB, Filiberti A, Montgomery M, Chitrakar A, Royer DJ, Carr DJJ. Herpes Simplex Virus 1 (HSV-1) 0ΔNLS Live-Attenuated Vaccine Protects against Ocular HSV-1 Infection in the Absence of Neutralizing Antibody in HSV-1 gB T Cell Receptor-Specific Transgenic Mice. J Virol 2020;94:e01000-20. [PMID: 32999018 DOI: 10.1128/JVI.01000-20] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Gmyrek GB, Berube AN, Sjoelund VH, Carr DJJ. HSV-1 0∆NLS vaccine elicits a robust B lymphocyte response and preserves vision without HSV-1 glycoprotein M or thymidine kinase recognition. Sci Rep 2022;12:15920. [PMID: 36151255 DOI: 10.1038/s41598-022-20180-0] [Reference Citation Analysis]
2 de Paiva CS, St Leger AJ, Caspi RR. Mucosal immunology of the ocular surface. Mucosal Immunol 2022. [PMID: 36002743 DOI: 10.1038/s41385-022-00551-6] [Reference Citation Analysis]
3 Rousseau A, Haigh O, Legrand R, Palgen JL, Lemaitre J, Deback C, Oziol N, Lomonte P, Labetoulle M. Initial TK-deficient HSV-1 infection in the lip alters contralateral lip challenge immune dynamics. Sci Rep 2022;12:8489. [PMID: 35590057 DOI: 10.1038/s41598-022-12597-4] [Reference Citation Analysis]
4 Carr DJJ, Berube A, Gershburg E. The Durability of Vaccine Efficacy against Ocular HSV-1 Infection Using ICP0 Mutants 0∆NLS and 0∆RING Is Lost over Time. Pathogens 2021;10:1470. [PMID: 34832625 DOI: 10.3390/pathogens10111470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 St Leger AJ, Koelle DM, Kinchington PR, Verjans GMGM. Local Immune Control of Latent Herpes Simplex Virus Type 1 in Ganglia of Mice and Man. Front Immunol 2021;12:723809. [PMID: 34603296 DOI: 10.3389/fimmu.2021.723809] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Carr DJJ, Berube AN, Filiberti A, Gmyrek GB. Lack of neonatal Fc receptor does not diminish the efficacy of the HSV-1 0ΔNLS vaccine against ocular HSV-1 challenge. Vaccine 2021;39:2526-36. [PMID: 33814229 DOI: 10.1016/j.vaccine.2021.03.075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]